For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development expenses | 3,457,032 | 5,841,871.5* | 4,576,389 | 4,212,918 |
| General and administrative expenses | 3,064,055 | 2,056,848* | 3,563,753 | 3,410,433 |
| Total operating expenses | 6,521,087 | 7,898,719.5 | 8,140,142 | 7,623,351 |
| Loss from operations | -6,521,087 | -7,898,719.5* | -8,140,142 | -7,623,351 |
| Interest income | 186,814 | 295,141.5* | 281,109 | 333,624 |
| Interest expense | 1,014,783 | 396,318.5* | 1,150,378 | 2,144,481 |
| Interest income (expenses), net | -827,969 | -101,177* | -869,269 | -1,810,857 |
| Loss before income taxes | -7,349,056 | -7,999,896.5* | -9,009,411 | -9,434,208 |
| Benefit for income taxes | 0 | -1,169,820* | 0 | 0 |
| Net loss | -7,349,056 | -6,830,076.5 | -9,009,411 | -9,434,208 |
| Basic EPS | -0.13 | -0.147 | -0.19 | -0.21 |
| Diluted EPS | -0.13 | -0.147 | -0.19 | -0.21 |
| Basic Average Shares | 55,496,279 | 46,380,807 | 46,869,531 | 45,902,502 |
| Diluted Average Shares | 55,496,279 | 46,380,807 | 46,869,531 | 45,902,502 |
PDS Biotechnology Corp (PDSB)
PDS Biotechnology Corp (PDSB)